APVO
Aptevo Therapeutics Inc (APVO)
Healthcare • NASDAQ • $4.97+2.26%
- Symbol
- APVO
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $4.97
- Daily Change
- +2.26%
- Market Cap
- $5.87M
- Trailing P/E
- N/A
- Forward P/E
- -0.27
- 52W High
- $258.12
- 52W Low
- $3.80
- Analyst Target
- $21.00
- Dividend Yield
- N/A
- Beta
- 1.65
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment malignant pleural mesothelioma, non-small cell lung, gastric/gastro-esophageal, head an…
Company websiteResearch APVO on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.